- Case report
- Open Access
Inspiratory laryngeal stridor as the main feature of progressive encephalomyelitis with rigidity and myoclonus: a case report and literature review
BMC Neurology volume 22, Article number: 42 (2022)
Progressive encephalomyelitis with rigidity and myoclonus (PERM) is an acute, potentially life-threatening, yet curable neuro-immunological disease characterized by spasms, muscular rigidity, and brainstem and autonomic dysfunction. The clinical features of glycine receptor (GlyR) antibody-positive PERM may be overlooked, particularly with some unusual symptoms.
A 52-year-old man was admitted to the hospital for evaluation of tension headache for 20 days and mild dysarthria. These symptoms were followed by panic, profuse sweating, severe dysarthria, dizziness, unsteady gait, and paroxysmal muscle spasms. Brain magnetic resonance imaging and cerebrospinal fluid analysis were normal. The patient’s condition steadily deteriorated. He repeatedly presented with rigidity, panic attacks, severe anxiety, paroxysmal inspiratory laryngeal stridor, cyanosis of the lips, and intractable epilepsy. Electromyography showed multiple myoclonic seizures, a single generalized tonic-clonic seizure, and a single generalized tonic seizure. Screening for autoimmune encephalitis antibodies revealed anti-GlyR antibodies in his cerebrospinal fluid. Immunomodulatory pulse therapy with steroids and immunoglobulin resulted in expeditious improvement of the symptoms within 2 weeks, and a follow-up at 5 weeks showed consistent clinical improvement.
Our case highlights that inspiratory laryngeal stridor is an important symptom of PERM. Our observation widens the spectrum of the clinical presentation of anti-GlyR antibody-positive PERM, where early identification is a key to improving prognosis.
Progressive encephalomyelitis with rigidity and myoclonus (PERM) is an acute, potentially life-threatening, yet curable neuroimmunological disease characterized by spasms, muscular rigidity, and brainstem and autonomic dysfunction. The clinical features, especially some unusual symptoms, may be overlooked in general neurologic exams. Since the initial description of glycine receptor antibodies (GlyR-Abs) in a patient with PERM in 2008, these antibodies have been reported in PERM and stiff-person syndrome (SPS) . GlyR-Abs were observed primarily in adults  and have been reported in over 100 patients . The main clinical symptoms of PERM are early brainstem involvement, including oculomotor disturbance and bulbar symptoms. Additional symptoms include spinal cord symptoms, autonomic symptoms , muscle spasms, cramps, and myoclonus. A relatively rare sign is epilepsy, stimulus-evoked startle, and respiratory failure. To date, repeated inspiratory laryngeal stridor as a symptom of PERM has not been reported. We present an illustrative case report and discuss relevant literature.
A 52-year-old man was admitted in November 2020, reporting a tension headache for 20 days. Brain computed tomography (CT, Fig. 1A) showed no obvious abnormality in the patient. He had a history of chronic pharyngitis and had felt pharyngeal discomfort 1 week before admission. An electronic laryngoscope showed chronic laryngitis (Fig. 1B). He had no history of major trauma, toxic exposure, or hereditary disease. Physical examination at admission showed clear consciousness and mild dysarthria but no other abnormal neurological signs.
Laboratory tests showed normal blood tests and blood coagulation parameters. Blood sugar (7.62 mmol/L) and homocysteine (61.82 μmol/L) levels were increased. Blood electrolyte and thyroid function levels were normal. Syphilis and human immunodeficiency virus antibodies were negative. Carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma antigen, carbohydrate antigen (CA) 724, prostate-specific antigen, neuron-specific enolase, alpha-fetoprotein, and cytokeratin 19 fragment levels were all normal. CA 199 (107 U/mL, reference range: 0–37 U/mL) and CA125 (36.9 U/mL, reference range: 0–35 U/mL) levels were increased. A 24-h dynamic electrocardiography showed occasional atrial and ventricular premature beats and ST-T changes. An initial brain magnetic resonance imaging (MRI, Fig. 1C) and brain magnetic resonance angiography showed no obvious abnormalities. Cervical spine MRI (Fig. 1D) showed cervical disc herniation.
On Day 2, the patient had an unsteady gait, distortion of the commissure, and mild panic. Repeated MRIs on Day 2 showed no apparent abnormalities (Fig. 1E). On Day 4, he had developed profuse sweating, dizziness, paroxysmal muscle spasms, and brisk tendon reflexes (Timeline). We initially diagnosed a suspected stroke. We started treatments to improve cerebral circulation, anti-platelets, lower lipids, and to releve his symptoms. However, his symptoms did not improve significantly.
On Day 11, the patient had a subarachnoid hemorrhage (Fig. 1F) caused by a fall, which could have occurred due to a tonic seizure. Physical examination at that time revealed drowsiness and a stiff neck. The patient repeatedly experienced loss of consciousness, clonic seizures, panic attacks unresponsive to olanzapine, and severe anxiety. Paroxysmal inspiratory laryngeal stridor (see Video) without three depression signs, obvious hypoxemia on a hand-held pulse oximeter, and cyanosis of the lips requiring occasional ventilation in status epilepticus were also observed. An electroencephalogram revealed frequent outbreaks of multispike and slow waves on all channels. Multiple myoclonic seizures, a single generalized tonic-clonic seizure, and a single generalized tonic seizure were detected on electromyography. We administered antiepileptic drugs (e.g., continuously pumped sodium valproate, intravenous diazepam, and oral levetiracetam), fluid rehydration, hemostasis, and symptomatic treatment. However, his epilepsy was not well controlled. Repeated head CTs (Fig. 1G) showed that the subarachnoid hemorrhage was absorbed after 1 month, but his condition did not improve.
On day 45, we performed cerebrospinal fluid (CSF) analysis and detected an anti-glycine receptor (anti-GlyR) antibody (1:100). The CSF culture was negative for bacteria, tubercle bacillus, and fungi. Antibodies for demyelination disease (including anti-aquaporin-4, anti-myelin basic protein, anti-myelin oligodendrocyte glycoprotein, anti-glial fibrillary acidic protein), autoimmune encephalitis (including anti-GAD, anti-NMDA, anti-IgLON5, anti-LGI1, anti-CASPR2, anti-DPPX, and anti- GABA), and paraneoplastic syndrome (including anti-Hu, anti-Ri, anti-Ma 1 and 2, anti-CV2, anti-Yo, anti-Tr, and anti-SOX1) in CSF were negative. Electronic gastroscopy was also performed. Electronic colonoscopy and biopsy showed a colon tubular adenoma with low-grade intraepithelial neoplasia.
We suspected anti-GlyR antibody-associated PERM. We began treatment with intravenous methylprednisolone (500 mg/d for 3 days, 240 mg/d for 3 days, 120 mg/d for 3 days, 80 mg/d for 3 days, which was switched to oral prednisone 60 mg/d for 1 month) and intravenous immunoglobulin 22.5 g/d for 5 days. His symptoms improved significantly, and no abnormalities were found on a repeat MRI (Fig. 1H). He was discharged after 13 days of immunotherapy. At 5 weeks after his discharge, the patient reported that the panic attacks, anxiety, and diaphoresis had improved. His gait was normal with no relapse of epilepsy, and the inspiratory laryngeal stridor almost disappeared. By contrasting the symptoms and signs before and after immunotherapy, the neurological symptoms (including dysarthria, dizziness, gait, and epilepsy), nonspecific symptoms (including atypical emotions and autonomic nervous dysfunction), and related signs were significantly improved, most returning to normal. He was satisfied with the treatment received and his recovery.
Discussion and conclusions
To date, a case of inspiratory laryngeal stridor as a clinical feature of PERM, which may be related to laryngeal spasm, and hypoventilation related to respiratory spasm has not been reported. The disease progresses rapidly, and if not treated in a timely manner, the patient may develop further respiratory failure.
GlyRs are chloride channels that are present mainly in the brainstem and spinal cord. GlyRs are also alkaloid strychnine targets associated with muscle spasms and cramps, muscle stiffness, agitation, stimulation-evoked seizures, myoclonus, respiratory failure, and sometimes death . Antibody-mediated inhibition of the GlyRs on the brainstem nuclei or spinal inhibitory interneurons may cause continuous firing of motor neurons. The excessive and paroxysmal response to various afferent impulses leads to increased stiffness, brainstem signs, trismus, myoclonus, spasms, or hyperekplexia . GlyR-Abs might disrupt glycinergic inhibition mechanisms, causing an excessive startle reflex.
Some patients had a prodrome, such as low mood, hallucinations, involuntary tic-like jerks , and flank tingling . These nonspecific prodromal symptoms can last for several weeks to months. Early recognition of prodrome is essential for diagnosis, but it is also difficult to identify.
Our patient had cyanosis, anxiety, brain stem dysfunction, profuse sweating, and palpitations. He also had inspiratory laryngeal stridor, which was followed by a clonic seizure. Similar to that observed in our patient, cyanosis secondary to hypoventilation may be associated with laryngospasm in people with epilepsy. Hypoventilation can be the result of restricted respiration due to high myodynamia (e.g., laryngospasm), but it also may be a manifestation of brain stem dysfunction. Our patient underwent a laryngoscopy for an upper airway obstruction, thought to be related to laryngeal spasm, which was ultimately ruled out. There is a report in the literature that hypoventilation improved with diazepam [7, 8]. Our patient’s symptoms improved with clonazepam. Hypoventilation is a serious complication of anti-GlyR-related PERM, at times manifesting with worsening rigidity and spasms in some patients . We need to pay attention to hypoventilation episodes, especially when exposed to respiratory suppressants, as these episodes increase the risk of respiratory failure.
In anti-GlyR-related PERM, psychological symptoms include phobias [8, 9], irritability, anxiety, and behavioral changes . Generalized anxiety and depression are also frequently reported . We observed hyperekplexia and severe anxiety in our patient, which improved following immunotherapy.
In our patient, multiple myoclonic seizures were detected on electromyography. No painful muscle spasms were noted, and their absence has also been noted in other reports . Rigidity and painful muscle spasms are the core clinical features of PERM . Generalized myoclonic jerks were triggered by sensory stimulation but also occurred spontaneously [7, 8].
Our patient did experience an unexpected generalized tonic seizure, which can frequently lead to falls and fractures. We found similar reports  in the literature. Although epilepsy is not the core symptom of PERM, anti-GlyR-related PERM can show intractable epilepsy [9, 10], as in our patient. Immunotherapy shows a beneficial effect.
Finally, our patient had profuse sweating and palpitations. Some patients reported in the literature had high blood pressure and hyperthermia . Patients are often reported to have prominent autonomic symptoms or even autonomic failure .
Our patient had normal cranial and spinal MRI scans with gadolinium. This finding is consistent with most MRIs in patients with GlyR-Abs-related PERM [6, 8, 12]. The CSF results in most patients were normal, with a minority of patients having mild inflammation [2, 6]. We found a colon tubular adenoma with low-grade intraepithelial neoplasia and rising CA levels in our patient. Malignancy screening in PERM is important. Approximately 10–20% of patients have an underlying malignant  or benign tumor, such as thymoma . However, many patients do not have tumors . We have recommended long-term follow-up for this patient.
Anti-GAD-Abs was not detected in our patient. Since PERM and SPS disorders can have overlapping clinical features, both GlyR- and GAD-Abs should be measured in patients with these clinical characteristics. Serum GlyR-Abs are the primary source of antibodies, and the titers are often higher than those in CSF . However, the clinical disease will depend on the access of antibodies from the serum to the brain . The antibody titers can correlate with disease severity . With immunotherapy, the antibody titers can be decreased [2, 12].
Immunomodulatory pulse therapy with steroids and immunoglobulin resulted in a significant and rapid improvement of symptoms in our patient. Many patients showed substantial and sustained improvement with immunotherapy, particularly combinations of corticosteroids , plasma exchange , intravenous immunoglobulin, or even immunoadsorption treatment . Patients with GlyR-Abs often improve with aggressive immunotherapy, and a mild decline in GlyR antibody serum titers indicates clinical improvement . There is often a clear response to immunotherapy in patients with neurological disorders associated with GlyR-Abs [11, 15]. For some patients with severe PERM, long-term immunotherapy is needed [2, 7] Relapses are not rare [6, 8], and subsequent immunotherapy treatments are effective [2, 6]. For some patients with refractory drug-resistant epilepsy, active immunotherapy is conducive to control epilepsy rapidly. Patients may not need long-term use of antiepileptic drugs after PERM is controlled. PERM typically progresses and then stabilizes over weeks to years. Some patients may relapse, and these episodes may lead to some sequelae . The prognosis is variable, but early, aggressive immunotherapy may contribute to a better prognosis. We have summarized the clinical features of the PERM patients with only positive GlyR-Abs according to the reported cases (see Table 1).
A limitation of this report is that the follow-up duration was short, and we did not perform PET-CT. A large-sample, multi-institution research program is needed in this respect.
In conclusion, our case highlights that inspiratory laryngeal stridor is one of the important symptoms of PERM. Patients with this symptom may further develop respiratory failure. It is vital to identify the clinical characteristics of PERM early to allow early aggressive immunotherapy, which may influence the prognosis. This case report broadens the clinical presentation spectrum of anti-GlyR-Abs and emphasizes the need to prevent serious complications early.
Availability of data and materials
Glycine receptor antibodies
Magnetic resonance imaging
Progressive encephalomyelitis with rigidity and myoclonus.
Crisp SJ, Balint B, Vincent A. Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors. Curr Opin Neurol. 2017;30:310–6. https://doi.org/10.1097/WCO.0000000000000450.
Stern WM, Howard R, Chalmers RM, Woodhall MR, Waters P, Vincent A, et al. Glycine receptor antibody mediated progressive encephalomyelitis with rigidity and myoclonus (PERM): a rare but treatable neurological syndrome. Pract Neurol. 2014;14:123–7. https://doi.org/10.1136/practneurol-2013-000511.
Su Y, Cui L, Zhu M, Liang Y, Zhang Y. Progressive encephalomyelitis with rigidity and myoclonus with thymoma: a case report and literature review. Front Neurol. 2020;11:1017. https://doi.org/10.3389/fneur.2020.01017.
Martinez-Martinez P, Molenaar PC, Losen M, Baets MH. Glycine receptor antibodies in PERM: a new channelopathy. Brain. 2014;137:2115–6. https://doi.org/10.1093/brain/awu153.
Iizuka T, Tominaga N, Kaneko J. Clinical spectrum of anti-glycine receptor antibody-associated disease. Clin Neurol. 2013;53:1063–6. https://doi.org/10.5692/clinicalneurol.53.1063.
Hutchinson M, Waters P, McHugh J, Gorman G, Riordan SO, Connolly S, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71:1291–2. https://doi.org/10.1212/01.wnl.0000327606.50322.f0.
Bourke D, Roxburgh R, Vincent A, Cleland J, Jeffery O, Dugan N, et al. Hypoventilation in glycine-receptor antibody related progressive encephalomyelitis, rigidity and myoclonus. J Clin Neurosci. 2014;21:876–8. https://doi.org/10.1016/j.jocn.2013.07.014.
Mas N, Saiz A, Leite MI, Waters P, Baron M, Castaño D, et al. Antiglycinereceptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry. 2011;82:1399–401. https://doi.org/10.1136/jnnp.2010.229104.
Schmidt C, Freilinger T, Lieb M, Rémi J, Klein M, Straube A, et al. Progressive encephalomyelitis with rigidity and myoclonus preceding otherwise asymptomatic Hodgkin’s lymphoma. J Neurol Sci. 2010;291:118–20. https://doi.org/10.1016/j.jns.2009.12.025.
Wuerfel E, Bien CG, Vincent A, Woodhall M, Brockmann K. Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder. J Neurol Sci. 2014;343:180–2. https://doi.org/10.1016/j.jns.2014.05.014.
Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178–92. https://doi.org/10.1093/brain/awu142.
Kenda J, Švigelj V, Rodi Z, Koritnik B, Graus F, Kojovic M. Glycine receptor antibodies and progressive encephalomyelitis with rigidity and myoclonus with predominant motor neuron degeneration–expanding the clinical spectrum. J Neurol Sci. 2015;353:177–8. https://doi.org/10.1016/j.jns.2015.03.049.
Borellini L, Lanfranconi S, Bonato S, Trezzi I, Franco G, Torretta L, et al. Progressive encephalomyelitis with rigidity and myoclonus associated with anti-GlyR antibodies and hodgkin’s lymphoma: a case report. Front Neurol. 2017;8:401. https://doi.org/10.3389/fneur.2017.00401.
Peeters E, Vanacker P, Woodhall M, Vincent A, Schrooten M, Vandenberghe W. Supranuclear gaze palsy in glycine receptor antibody-positive progressive encephalomyelitis with rigidity and myoclonus. Mov Disord. 2012;27:1830–2. https://doi.org/10.1002/mds.25239.
Martinez-Hernandez E, Arino H, McKeon A, Iizuka T, Titulaer MJ, Simabukuro MM, et al. Clinical and immunologic investigations in patients with stiff-person spectrum disorder. JAMA Neurol. 2016;73:714–20. https://doi.org/10.1001/jamaneurol.2016.0133.
This study was supported by shenzhen city of science and technology planning projects (No. JCYJ20180507184647636 and KJYY20180703165202011).
The funder’s role was limited to providing English editing of the manuscript, and they did not participate in the conduct of this study.
Ethics approval and consent to participate
The study design was approved by the ethics review board of Quanzhou First Hospital Affiliated with Fujian Medical University (No:2021–112). Informed consent was obtained from the patient in the study.
Consent for publication
We obtained written consent for publication from the patient.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Yao, Q., Fu, M., Ren, L. et al. Inspiratory laryngeal stridor as the main feature of progressive encephalomyelitis with rigidity and myoclonus: a case report and literature review. BMC Neurol 22, 42 (2022). https://doi.org/10.1186/s12883-022-02555-y
- Anti-glycine receptor antibody
- Progressive encephalomyelitis with rigidity and myoclonus
- Inspiratory laryngeal stridor
- Case report